On the leading edge of Personalized Medicine, Big Data Analytics and BioPharmaceutical R&D for ~20 years, Iris is the Chief Therapeutics Officer of Eleven Therapeutics, where she oversees the strategy and development of novel RNA-based therapeutics discovered by the company’s platform, which uniquely marries between combinatorial chemistry and A.I. to decipher the structure-activity relationship of durable, effective and safe respiratory and metabolic therapeutics. Prior to joining Eleven, Iris served in Chief Scientific Officer roles (CAMP4, Amide Technologies (acting)) and consulted for top VCs in the Boston area. Prior to that, Iris held leadership positions in, or consulted for top Big Pharma (GSK, Eli Lily, Takeda and Teva – where she was VP, Head of Early-Stage Development). She specializes in leveraging multi-dimensional genomic insights and eHealth as engines of therapeutic discovery, development and lifecycle management across a wide range of modalities and therapeutic areas. Iris serves as chairman of the SAB at BC Platforms, and as Strategic Scientific Advisor at Modulight.bi, and CGRP Diagnostics. Dr. Grossman earned her B.Sc. in medicine at the Technion, and a Ph.D. in medicine, population genomics and pharmacogenetics from the Technion, co-mentored with the Weizmann Institute. Her post-doc fellowship in Personalized Medicine and Population Genomics was completed at Duke university.